Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
40
GEHC Quote, Financials, Valuation and Earnings
Last price:
$72.05
Seasonality move
:
-1.91%
Day range:
$69.49 - $71.39
52-week range:
$57.65 - $94.80
Dividend yield:
0.18%
P/E ratio:
14.98x
P/S ratio:
1.65x
P/B ratio:
3.55x
Volume:
3.1M
Avg. volume:
3.5M
1-year change:
-10.12%
Market cap:
$32.6B
Revenue:
$19.7B
EPS (TTM):
$4.75
Analysts' Opinion
-
Consensus RatingGE HealthCare Technologies has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $87.40, GE HealthCare Technologies has an estimated upside of 22.83% from its current price of $71.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $73.00 representing 100% downside risk from its current price of $71.16.
Fair Value
-
According to the consensus of 17 analysts, GE HealthCare Technologies has 22.83% upside to fair value with a price target of $87.40 per share.
GEHC vs. S&P 500
-
Over the past 5 trading days, GE HealthCare Technologies has underperformed the S&P 500 by -2.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GE HealthCare Technologies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GE HealthCare Technologies has grown year-over-year revenues for 4 quarters straight. In the most recent quarter GE HealthCare Technologies reported revenues of $4.8B.
Earnings Growth
-
GE HealthCare Technologies has grown year-over-year earnings for 5 quarters straight. In the most recent quarter GE HealthCare Technologies reported earnings per share of $1.23.
Enterprise value:
39.1B
EV / Invested capital:
2.15x
Price / LTM sales:
1.65x
EV / EBIT:
12.06x
EV / Revenue:
1.98x
PEG ratio (5yr expected):
0.39x
EV / Free cash flow:
28.47x
Price / Operating cash flow:
23.77x
Enterprise value / EBITDA:
10.26x
Gross Profit (TTM):
$8.3B
Return On Assets:
6.64%
Net Income Margin (TTM):
11.03%
Return On Equity:
25.89%
Return On Invested Capital:
12.31%
Operating Margin:
13.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $18.7B | $19.5B | $19.8B | $4.7B | $4.8B | |
| Gross Profit | $7.4B | $7.9B | $8.3B | $1.9B | $2B | |
| Operating Income | $2.6B | $2.4B | $2.7B | $540M | $628M | |
| EBITDA | $3.4B | $3.5B | $3.8B | $798M | $939M | |
| Diluted EPS | $3.86 | $3.42 | $4.75 | $0.81 | $1.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $9.6B | $9.4B | $9.7B | |
| Total Assets | -- | -- | $32.6B | $32.2B | $33.6B | |
| Current Liabilities | -- | -- | $8.2B | $8.9B | $10B | |
| Total Liabilities | -- | -- | $25.9B | $24.6B | $24.2B | |
| Total Equity | -- | -- | $6.7B | $7.6B | $9.4B | |
| Total Debt | -- | -- | $10.2B | $9.3B | $8.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.1B | $2.1B | $1.8B | $419M | $250M | |
| Cash From Investing | -$564M | -$480M | -$1.1B | -$188M | -$407M | |
| Cash From Financing | $271M | -$1.3B | -$706M | -$153M | -$286M | |
| Free Cash Flow | $1.8B | $1.7B | $1.4B | $274M | $98M | |
GEHC
Sector
Market Cap
$32.6B
$32.8M
Price % of 52-Week High
75.06%
46.28%
Dividend Yield
0.18%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-10.12%
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0.18%
Annualized payout:
$0.12
Payout ratio:
2.61%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$72.14
200-day SMA
Sell
Level
$81.17
Bollinger Bands (100)
Sell
Level
67.15 - 86.01
Chaikin Money Flow
Buy
Level
71.5M
20-day SMA
Sell
Level
$71.58
Relative Strength Index (RSI14)
Sell
Level
48.38
ADX Line
Sell
Level
11.37
Williams %R
Neutral
Level
-61.8557
50-day SMA
Buy
Level
$69.44
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-30.1M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9301)
Sell
CA Score
(Annual)
Level (-1.0095)
Buy
Beneish M-Score
(Annual)
Level (-2.4535)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.2434)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company’s sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Stock Forecast FAQ
In the current month, GEHC has received 12 Buy ratings 5 Hold ratings, and 0 Sell ratings. The GEHC average analyst price target in the past 3 months is $87.40.
-
Where Will GE HealthCare Technologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that GE HealthCare Technologies share price will rise to $87.40 per share over the next 12 months.
-
What Do Analysts Say About GE HealthCare Technologies?
Analysts are divided on their view about GE HealthCare Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GE HealthCare Technologies is a Sell and believe this share price will drop from its current level to $73.00.
-
What Is GE HealthCare Technologies's Price Target?
The price target for GE HealthCare Technologies over the next 1-year time period is forecast to be $87.40 according to 17 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is GEHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GE HealthCare Technologies is a Buy. 12 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GEHC?
You can purchase shares of GE HealthCare Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GE HealthCare Technologies shares.
-
What Is The GE HealthCare Technologies Share Price Today?
GE HealthCare Technologies was last trading at $72.05 per share. This represents the most recent stock quote for GE HealthCare Technologies. Yesterday, GE HealthCare Technologies closed at $71.16 per share.
-
How To Buy GE HealthCare Technologies Stock Online?
In order to purchase GE HealthCare Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 2.76% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 3.14% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 12.72% over the past day.
